<DOC>
	<DOCNO>NCT01414153</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 4 monthly injection iSONEP give alone combination Lucentis , Avastin Eylea subject wet Age-related Macular Degeneration ( AMD ) . iSONEP anti-permeability effect , also anti-angiogenic , anti-inflammatory , anti-fibrotic property . The drug may therefore ability achieve good visual outcome Lucentis , Avastin Eylea , particularly subject demonstrate robust response Lucentis , Avastin Eylea several monthly injection . Further , combination Lucentis , Avastin Eylea iSONEP may additive synergistic . By inhibit multiple mechanism contribute exudative-AMD-related vision loss , good visual outcome may possible Lucentis , Avastin Eylea alone .</brief_summary>
	<brief_title>Efficacy Safety Study iSONEP With &amp; Without Lucentis/Avastin/Eylea Treat Wet AMD</brief_title>
	<detailed_description>The study conduct subject qualify `` sub-responders '' Lucentis , Avastin Eylea meaning subject ( ) residual subretinal intra-retinal fluid observe Cirrus Spectralis Spectral Domain Optical Coherence Tomography ( SD-OCT ) , ( ii ) leakage fluorescein angiogram ( FA ) , ( iii ) average central subfield thickness ≥250 μm . Additionally , subject previously receive minimum 3 intravitreous ( IVT ) injection Lucentis , Avastin Eylea within 12-month period prior screen . Screening must occur 28 65 day subject 's last Lucentis Avastin treatment 42 79 day subject 's last Eylea treatment . Subjects must dose within 14 day screen , day initial study treatment ( Day 0 ) , meet follow criterion : ( ) Early Treatment Diabetic Retinopathy Study ( ETDRS ) Best-corrected visual acuity ( BCVA ) ≥25 ≤73 letter ( approximately 20/320 20/40 Snellen scale ) , ( ii ) residual subretinal intra-retinal fluid observe Cirrus Spectralis SDOCT , ( iii ) leakage FA .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>≥50 year age diagnosis wet AMD Subjects receive 3 injection Lucentis Avastin Eylea within 12 month prior screen Active subfoveal CNV secondary AMD ( leakage FA ) Presence residual subretinal intraretinal fluid Cirrus Spectralis SDOCT SDOCT 1 mm central macular subfield retinal map analysis ≥250 μm screen ETDRS BCVA ≥25 ≤73 letter ( approximately 20/320 20/40 Snellen scale ) screen Day 0 In fellow eye , ETDRS BCVA 20/400 well Subject serous pigment epithelial detachment ( PED ) ( part may subfoveal ) intraretinal and/or subretinal fluid may include Most recent IVT injection Lucentis Avastin few 28 day 65 day prior screen Most recent IVT injection Eylea few 42 day 79 day prior screen Previous photodynamic therapy ( PDT ) Macugen® time point Focal thermal laser grid laser within 3 month prior Day 0 Use IVT , subtenon subconjunctival steroid within 3 month prior Day 0 Use topical ophthalmic corticosteroid 2 week prior Day 0 Intraocular surgery , include cataract surgery , / laser type within 3 month prior Day 0 anticipate need ocular surgery ophthalmic laser treatment study period Subjects previously treat , currently receive treatment another investigational agent device neovascular AMD study eye Retinal total lesion size &gt; 12 disc area ( 30.5 mm2 ) , include blood , scar neovascularization assess FA study eye Presence fibrovascular PED extend underneath center fovea Presence retinal angiomatous proliferation ( RAP ) lesion Presence polypoidal choroidal vasculopathy ( PCV ) ( suspect , Indocyanine Green Angiography ( ICG ) perform discretion Investigator ) Subretinal hemorrhage study eye follow true : ( ) subretinal hemorrhage represent 50 % total lesion area ; ( ii ) subfoveal blood 1 disc area size ( iii ) subfoveal blood fovea surround less 270 degree visible CNV FA Scar fibrosis make &gt; 50 % total lesion area study eye Anatomic damage center fovea include fibrosis , scar atrophy History retinal pigment epithelial tear History vitreous hemorrhage within 4 week prior screen study eye Clinical evidence diabetic retinopathy , diabetic macular edema vascular disease affect retina , AMD , either eye Uncontrolled glaucoma define : ( ) intraocular pressure ≥25 mmHg despite treatment anti glaucoma medication study eye ( ii ) Investigator Prior trabeculectomy filtration surgery study eye ( prior laser trabeculoplasty allow )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>choroidal neovascularization</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>iSONEP</keyword>
	<keyword>sonepcizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>Eylea</keyword>
	<keyword>aflibercept</keyword>
</DOC>